Table HIV dementia hazard ratios for CPE score, HIV-CAUSAL collaboration, 1998-2013

CPE score	Person-years		No. of events		Unadjusted hazard ratio (95% CI)		IPW-adjusted hazard ratio (95% CI)	
	Overall	Excluding efavirenz	Overall	Excluding efavirenz	Overall	Excluding efavirenz	Overall	Excluding efavirenz
Low	140,962	82,323	127	95	1.00 (Reference)	1.00 (Reference)	1.00 (Reference)	1.00 (Reference)
Medium	86,799	46,219	72	46	0.97 (0.72, 1.30)	0.98 (0.68, 1.40)	1.01 (0.73, 1.39)	1.04 (0.72, 1.50)
High	32,097	28,930	36	34	1.55 (1.06, 2.26)	1.33 (0.89, 1.98)	1.74 (1.15, 2.65)	1.80 (1.10, 2.95)

Abbreviations: CI = confidence interval; CPE = CNS penetration effectiveness; IPW = inverse probability weighting.

symptoms or neuropsychiatric issues. Efavirenz is commonly used as part of the regimens with low and medium CPE scores. However, an analysis that excludes individuals initiating a regimen with efavirenz does not materially affect our results (table). We agree with Beardsley and Le that future studies are needed to examine the effect of CNS penetration on the incidence of HIV dementia.

© 2015 American Academy of Neurology

1. Caniglia EC, Cain LE, Justice A, et al. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. *Neurology* 2014;83:134-141.
2. Berger JR, Clifford DB. The relationship of CPE to HIV dementia: slain by an ugly fact? *Neurology* 2014;83:109-110.
3. World Health Organization. March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Available at: www.who.int/hiv/pub/guidelines/arv2013/arvs2013supplement_march2014/en/. Accessed July 22, 2014.

CORRECTION

Novel *CLN3* mutation causing autophagic vacuolar myopathy

In the article "Novel *CLN3* mutation causing autophagic vacuolar myopathy" by A. Cortese et al. (*Neurology*® 2014;82:2072-2076), there is an error in the Results regarding the *ASPHDI* variant. The *ASPHDI* variant should have been described as a duplication: c.513_515dup resulting in p.(Gly172dup), which might retain some functionality (this is a known issue with the software used to annotate the variants in the whole exome sequencing data). The authors regret the error.

Neurology®

Novel *CLN3* mutation causing autophagic vacuolar myopathy

Neurology 2015;84;633

DOI 10.1212/WNL.0000000000001246

This information is current as of February 9, 2015

Updated Information & Services

including high resolution figures, can be found at:
<http://n.neurology.org/content/84/6/633.full>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2015 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.